TCF7L2 and diabetes mellitus: The mechanisms by which TCF7L2 polymorphisms increase diabetes risk and affect the treatment response to insulin secretagogues were thought to be related to impaired incretin-induced insulin secretion, impaired suppression of glucagon or impaired glucagon-like peptide-1 secretion [10–13].